Navigation Links
Stallergenes S.A.: Positive Results From a Phase IIb/III Clinical Trial on the House Dust Mite Desensitization Tablet
Date:4/29/2009

ge symptom score has been improved by 20% in both treated groups. In particular, the nasal congestion score has been improved by 40% (median) and the nasal pruritus by 32% (median). The safety profile has been highly satisfactory.

For the same level of efficacy, the 300 IR tablet has been selected.

Furthermore, the onset of action was achieved from the 4th month of treatment, meaning that the difference between the placebo and the treated groups was statistically significant, the treatment effect being maintained at the same level up to the end of the study.

The quality of life has been statistically improved and the proportion of symptom-controlled days increased by 52%.

The study will be pursued over 1 year on an observational basis in accordance with protocol.

"The conduct of clinical trials in perennial allergic rhinitis is a major challenge. The outcomes of the VO57.07 are clearly good and consistent, clinically important and relevant", said Prof. Karl-Christian Bergmann, international coordinator of the study. "These results are more than promising for the roll-over of the development of house dust mites sublingual desensitization therapy".

About House Dust Mites Allergic Rhinitis

In Europe, on average, almost 40% of respiratory allergic conditions are caused by house dust mites, making this the leading cause of respiratory allergy ahead of grass pollens. From early childhood, house dust mites can trigger allergic rhinitis, worsening over time with a natural progression towards asthma. The symptoms may be severe, significantly impairing patients' quality of life.

About the Stalair(R) Development Program

According to World Health Organization (WHO) estimates, 20 to 25% of the world's population currently suffers from respiratory allergic symptoms (rhinoconjunctivitis, rhinitis and/or asthma). By 2020, 50% of the world
'/>"/>

SOURCE Stallergenes
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. STALLERGENES: Oralair(R) Grasses Obtains a Pediatric MA(1) in Germany
2. Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber
3. Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
4. Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication
5. Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
6. Study Data Show Positive European Experience With DuraHeart Left Ventricular Assist Device for Advanced Stage Heart Failure Patients
7. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
8. Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity
9. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
10. DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
11. Cardiums InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Global ... Systems -- Focus on End Users ... OBJECTIVES A drug delivery system ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
(Date:1/14/2014)... 2014 InformEx, North America,s leading ... will hold the 30 th edition of its annual ... Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... fine chemical and specialty chemical companies will take part in ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
(Date:4/17/2014)... the first genetic variant specifically associated with the ... around 10-15 per cent of all breast cancer ... breast cancer sub-type, called invasive lobular carcinoma, gives ... this particular kind of breast cancer, which can ... today (Thursday) in the journal PloS Genetics ...
(Date:4/17/2014)... most popular vaccine brands for children may not be ... some cost factors when choosing vaccines, driving the market ... to a new study by University of Illinois researchers. ... driven by numerous factors," says Sheldon H. Jacobson, a ... science and of mathematics at the U. of I. ...
(Date:4/17/2014)... Experimental Biology and Medicine a multidisciplinary ... Paul Kenis in the Institute of Genomic Biology ... Illinois Urbana-Champaign describe their recent work on subcellular ... of cell functions including energy metabolism, signaling, and ... regulating normal cellular behavior, redox status has been ...
(Date:4/17/2014)... Two recent papers by a University of ... help scientists develop treatments or vaccines for Dengue ... and other disease-causing flaviviruses. , Jeffrey S. Kieft, ... at the School of Medicine and an early ... and colleagues recently published articles in the scholarly ...
(Date:4/17/2014)... McCullers, MD, was recently invited to submit a ... Reviews Microbiology , one of the world,s foremost ... disease specialist, and chair of the Department of ... Center, analyzed the epidemiology and microbiology of co-infections ... well as more recent 2009 novel H1N1 pandemic. ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study recalculates costs of combination vaccines 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:CU researchers discover target for treating dengue fever 2
... of Catholics for Choice, issued the following statement on Respect ... Catholic Bishops holds its annual Respect Life Sunday. On this ... also respect the truth. A recent publication by the USCCB, ... on healthcare reform prove that the bishops, desire to promote ...
... , WILMINGTON, Del., Oct. 2 Nationwide Health ... of 4,000 production transactions processed through the NHIN ... CONNECT solution. , CONNECTfx was developed ... NHIEs, HIEs, and other collaborative healthcare organizations by ...
... NASHVILLE, Tenn., Oct. 2 Brookdale Senior Living Inc. (NYSE: ... Chief Financial Officer, will make a presentation regarding the Company ... New York on Monday, October 5, 2009, beginning at 3:30 ... live and can be accessed on the Internet at ...
... risk rises when transfused blood is more than 28 days old, ... suffered severe trauma and are given a major transfusion of red ... are twice as likely to die as those who receive fresher ... of 202 severe trauma patients who were treated with five or ...
... Oct. 2 Brent Phillips, a senior executive at ... officer of Aurora Medical Group. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090303/CG78204LOGO-b ... the 960-physician medical group. , "Brent will ... Jeff Bailet, M.D., president of Aurora Medical Group. ...
... a long way in the last decade. Today, one can talk, ... even access the Web. Now imagine a cell phone that can ... test water quality after a major disaster like a hurricane or ... engineering at UCLA,s Henry Samueli School of Engineering and Applied Science, ...
Cached Medicine News:Health News:Respect Life and the Truth on Respect Life Sunday 2Health News:Respect Life and the Truth on Respect Life Sunday 3Health News:NHIT Processes Over 4,000 Production Transactions, Advances Adoption of NHIN Initiative 2Health News:Fresh Blood Boosts Survival in Trauma Patients 2Health News:Mayo Clinic Executive Brent Phillips to Join Aurora Medical Group as Chief Operating Officer 2Health News:NIH recognizes engineering professor's innovative research with major award 2Health News:NIH recognizes engineering professor's innovative research with major award 3
The Aortic Root Cannulae With Vent Line are flanged, with radiopaque tips; two side holes in tip....
The KAVD Venous Cannula is the first of its kind. It is a combination of cannulae/venous line designed to "bridge the gap between the patient and the Medtronic Resting Heart System circuit....
... Medtronic Select CAP® cannulae provides a ... pressure readings. An innovative combination of ... monitoring line, the Select CAP® can ... central arterial pressure readings on which ...
Intermittent catheter...
Medicine Products: